Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type”

7 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 7 of 7 results

Large-scale testing (Phase 3)Looking for participantsNCT06561048
What this trial is testing

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Who this might be right for
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaFollicular T-Cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc. 150
Early research (Phase 1)Active Not RecruitingNCT02520791
What this trial is testing

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Who this might be right for
Advanced Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeRecurrent Grade 1 Follicular Lymphoma+16 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Looking for participantsNCT06035497
What this trial is testing

Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Who this might be right for
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb 85
Large-scale testing (Phase 3)Looking for participantsNCT06522737
What this trial is testing

Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype

Who this might be right for
Lymphoma
SecuraBio 124
Large-scale testing (Phase 3)WithdrawnNCT04021082
What this trial is testing

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

Who this might be right for
Peripheral T-Cell Lymphoma (PTCL NOS)Nodal Lymphomas of T Follicular Helper (TFH)Follicular T-cell Lymphoma (FTCL)+6 more
Portola Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT04251065
What this trial is testing

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Who this might be right for
Refractory T-Cell LymphomaRelapsed T-Cell Lymphoma
Fondazione Italiana Linfomi - ETS 8
Testing effectiveness (Phase 2)Temporarily pausedNCT06761677
What this trial is testing

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

Who this might be right for
Relapsed or Refractory Lymphoma Including ENKL
SymBio Pharmaceuticals 43
21